B2AD-Risk: How atrial fibrillation burden changes after ischemic stroke
Official title: Evolution of Burden of AF Biomarkers, Left Atrial Characteristics, Demographics,and Risk Factors in AF Detected After Stroke
Run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · NCT06589700 · Data updated 2026-11-12
This project will try continuous implantable heart-rhythm monitoring to see how atrial fibrillation changes over time in people newly diagnosed with AF after an ischemic stroke.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 24 (estimated) |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Locations | 1 site (London, Ontario) |
| Status | Recruiting |
| Started | October 16, 2025 |
| Main results expected | October 2027 |
| Study ends | October 2027 |
| Registry record updated | May 7, 2026 |
| Trial ID | NCT06589700 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with a recent cortical or subcortical ischemic stroke who were newly diagnosed with paroxysmal AF (known before stroke, detected on admission ECG, or detected on 14-day Holter) and who agree to receive an implantable loop recorder.
✕Probably not a fit
Patients with permanent or persistent AF, those unwilling to undergo an implantable monitor, or those with relevant contraindications (for example allergy to iodinated contrast agents) are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will implant loop recorders in adults who had a recent cortical or subcortical ischemic stroke and were newly diagnosed with paroxysmal AF to continuously record heart rhythms. They will track changes in AF episode frequency and duration, measure blood biomarkers of cardiac health, and image the left atrium to follow size and function over time. Patients will be grouped by how their AF was first detected (known before stroke, found on admission ECG, or found on 14-day Holter) and followed with regular clinic visits. Permanent or persistent AF and inability to consent are exclusion criteria; all procedures occur at a single center.
Why it matters
Potential benefit: If successful, the findings could help doctors better tailor anticoagulation and other stroke-prevention strategies by revealing which patients develop more frequent or severe AF after stroke.
How similar studies have gone: Prior intensive cardiac-monitoring studies after ischemic stroke have successfully detected new AF and informed anticoagulation decisions, so this work builds on established monitoring methods.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with cortical or subcortical, cryptogenic or non-cryptogenic acute ischemic stroke * Any of the following types of AF: * Paroxysmal AF known before stroke onset (KAF). * Paroxysmal AF found on an admission or Emergency Department ECG (ECG-AFDAS) * Paroxysmal AF found on 14-day Holter monitoring (PCM-AFDAS) Exclusion Criteria: * Patients not willing to consent * Permanent or persistent AF * Allergy to iodinated contrast agents
Where it's running
-
Heart and Brain Lab, Western University
London, Ontario, Canada Recruiting
Study contacts
- Principal investigator: Luciano A Sposato, MD — Western University
- Study coordinator: Diana Ayan, Pharm MSc
- Email: diana.ayan@lhsc.on.ca
- Phone: 519-685-8500
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Apixaban with or without Clopidogrel in stroke patients with NVAF and intracranial/extracranial atherosclerosis
This study tests whether adding clopidogrel to apixaban is safe and helpful for people with acute ischemic stroke due to non-valvular atrial fibrillation and atherosclerosis.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Heart assessment to check repeat-stroke risk in people with atrial fibrillation
This project will test whether detailed heart examinations can find which people with atrial fibrillation who just had an ischemic stroke are at high risk of having another stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
Stroke prevention in ischemic stroke with covert atrial fibrillation
This trial tests whether starting apixaban or aspirin after a recent ischemic stroke with suspected but undetected atrial fibrillation can prevent future strokes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.